Woodline Partners’s Protara Therapeutics TARA Stock Holding History

Woodline Partners’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-851,674	Closed	-$2.58M	–	1042
2025 Q2	$2.58M	Hold	851,674	–	–	0.01%	685
2025 Q1	$3.63M	Sell	851,674 -1,486	-0.2%	-$6.64K	0.02%	577
2024 Q4	$4.5M	Buy	853,160 +1,593	+0.2%	+$5.15K	0.03%	506
2024 Q3	$1.56M	Buy	851,567 +751,566	+752%	+$1.54M	0.01%	488
2024 Q2	$208K	Buy	+100,001	New	+$292K	﹤0.01%	533

Other funds holding TARA

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Woodline Partners's TARA Position: Q3 2025 in Review

Woodline Partners sold out of Protara Therapeutics (TARA) in Q3 2025, closing a stake of 851,674 shares — an estimated $2.58M sold.

Woodline Partners first reported a position in TARA in Q2 2024 and held it in 5 quarters. The position peaked at $4.5M in Q4 2024. 81 funds tracked by Wall St. Rank hold TARA as of Q3 2025.

Woodline Partners reported no remaining Protara Therapeutics position as of Q3 2025 after selling out during the quarter.
Woodline Partners sold 851,674 Protara Therapeutics shares in Q3 2025, an estimated $2.58M.
Woodline Partners first reported a position in Protara Therapeutics in Q2 2024 and held it in 5 quarters.
Woodline Partners's Protara Therapeutics position peaked at $4.5M in Q4 2024.
81 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2025.

Based on Woodline Partners's 13F filing for Q3 2025, filed 14 Nov 2025.